The First Nations Health Authority (FNHA) has announced that it will now provide reimbursement for a vaccine that offers protection against Respiratory Syncytial Virus (RSV). This coverage is effective immediately, ensuring increased protection for both pregnant individuals and their babies.
Coverage Details
First Nations Health Benefits will accept reimbursement requests for vaccinations with the Abrysvo™ vaccine administered on or after August 25, 2024. Coverage applies to pregnant individuals who were 32 to 36 weeks gestation at the time of administration.
To request reimbursement, clients must complete the FNHA Reimbursement Form.
Why Protect Against RSV?
RSV is a common virus that circulates during fall and winter, spreading easily through coughs, sneezes, or contact with contaminated surfaces. While it typically causes mild cold-like symptoms in most individuals, RSV poses a significant risk to babies under six months of age. In infants, RSV can lead to severe complications such as bronchiolitis (inflammation of the small airways in the lungs) and pneumonia.
A Proactive Approach for the 2024/2025 RSV Season
For the 2024/2025 RSV season, limited doses of the infant antibody Nirsevimab are available through BC Children's Hospital for some eligible infants. However, for those not eligible, the FNHA strongly recommends that pregnant mothers consider the Abrysvo™ vaccine during the 32 to 36 weeks of pregnancy.
This vaccine provides dual protection:
For the pregnant parent: Enhanced immunity during the RSV season.
For the baby: A 60% reduction in the risk of hospitalization due to RSV during their first RSV season.
The cost of the vaccine is fully covered through FNHA Health Benefits for eligible individuals.
Next Steps
Talk to your family doctor, nurse practitioner, or community health nurse to learn more about Abrysvo™ or Nirsevimab and how they can help protect your baby from RSV.
Additional Resources
